Fecal microbiota transplantation for Clostridium difficile-associated diarrhea

Israel Medical Association Journal

Volumn 17, Issue 8, 2015, Pages 510-514

  Cohen, Nathaniel A ^a   Ami, Ronen Ben ^a   Guzner Gur, Hanan ^a   Santo, Moshe E ^a   Halpern, Zamir ^a   Maharshak, Nitsan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bacteriotherapy; Clostridium difficile; Diarrhea; Fecal microbiota transplantation (FMT); Gut microbiome

Indexed keywords

METRONIDAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT;

CLOSTRIDIUM DIFFICILE INFECTION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DONOR SELECTION; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; FECES MICROFLORA; FOLLOW UP; HUMAN; ILEUS; IMMUNE RESPONSE; IMMUNOAFFINITY CHROMATOGRAPHY; MEDICAL PROCEDURES; META ANALYSIS (TOPIC); PATIENT ATTITUDE; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SAFETY; SCREENING; THERAPY EFFECT; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; GASTROINTESTINAL TRACT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MICROFLORA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY; TRANSPLANTATION;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; GASTROINTESTINAL TRACT; HUMANS; MICROBIOTA; OUTCOME ASSESSMENT (HEALTH CARE); TRANSPLANTS;

EID: 84940378471     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012; 55 (Suppl 2): S65-70.
2. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 2012; 67 (3): 742-8.
3. Oldfield IV EC, Oldfield III EC, Johnson DA. Clinical update for the diagnosis and treatment of Clostridium difficile infection. World J Gastrointest Pharmacol Ther 2014; 5 (1): 1-26.
4. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107 (7): 1001-10.
5. Mahida YR, Makh S, Hyde S, Gray T, Borriello SP. Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. Gut 1996; 38 (3): 337-47.
6. Souza MH, Melo-Filho AA, Rocha MF, et al. The involvement of macrophagederived tumour necrosis factor and lipoxygenase products on the neutrophil recruitment induced by Clostridium difficile toxin B. Immunology 1997; 91 (2): 281-8.
7. Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458 (7242): 1176-9.
8. Fekety R. Guidelines for the diagnosis and management of Clostridium difficileassociated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92 (5): 739-50.
9. Samra Z, Madar-Shapiro L, Aziz M, Bishara J. Evaluation of a new immunochromatography test for rapid and simultaneous detection of Clostridium difficile antigen and toxins. IMAJ 2013; 15 (7): 373-6.
10. Brown WR. Fecal microbiota transplantation in treating Clostridium difficile infection. J Dig Dis 2014; 15 (8): 405-8.
11. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infection control and hospital epidemiology. Hosp Epidemiol Am 1999; 20 (1): 43-50.
12. Zhang F, Luo W, Fan Z, Ji G. Should we standardize the 1700 year old fecal microbiota transplantation? Am J Gastroenterol 2012;10711:755
13. Zhou H, Bei JF. Ge H (Dongjin Dynasty). Tianjin: Tianjin Science & Technology Press, 2000.
14. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 2004; 38 (6): 475-83.
15. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44 (5): 854-9.
16. Schwan A, Sjolin S, Trottestam U, Aronsson B. Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet 1983; ii (8354): 845.
17. Borody TJ, Paramsothy S, Agrawal G. Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep 2013; 15 (8): 337.
18. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9 (12): 1044-9.
19. Karlsson FH, Fak F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nature Comm 2012; 3: 1245.
20. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53 (10): 994-1002.
21. Dutta SK, Girotra M, Garg S, et al. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2014; 12 (9): 1572-6.
22. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nature Rev Gastroenterol Hepatol 2012; 9 (2): 88-96.
23. Garborg K, Waagsbo B, Stallemo A, Matre J, Sundoy A. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis 2010; 42 (11-12): 857-61.
24. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107 (7): 1079-87.
25. Mattila E, Uusitalo-Seppala R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012; 142 (3): 490-6.
26. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368 (5): 407-15.
27. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014; 48 (8): 693-702.
28. Lawley TD, Clare S, Walker AW, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathogens 2012; 8 (10): e1002995.
29. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489 (7415): 242-9.
30. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014; 109 (7): 1065-71.
31. Louie T, Cannon K, O'grady H, Wu K, Ward L. Fecal microbiome transplantation (FMT) via oral fecal microbial capsules for recurrent Clostridium difficile infection (rCDI). Abstract 2013, presented at IDWeek October 2013, San Francisco, CA
32. Khanna S, Pardi DS, Kelly C, et al. Clinical Evaluation of SER 109, a rationally designed, oral microbiome-based therapeutic for the treatment of recurrent Clostridium difficile. 2014. Available online: http://www.gastro.org/pressroom/ James_W._Freston_Abstract_Orally_Delivered_Microbes.pdf (Accessed August 12th 2015)
33. Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013; 1 (1): 3.
34. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44 (6): 846-8.
35. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51 (8): 2716-19.
36. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364 (5): 422-31.
37. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362 (3): 197-205.
38. Wang H, Sun X, Zhang Y, et al. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun 2012; 80 (8): 2678-88.
39. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. Clostridium difficile: development of a novel candidate vaccine. Vaccine 2012; 30 (29): 4307-9.
40. Pasteur S. 2013. Available from: http://www.sanofipasteur.com/en/commitment/ r-d/vaccines_for_tomorrow/.